Mednet Logo

What factors besides disease progression would lead you to de-intensify or change MM therapy for a patient with ongoing response?

In your experience, do certain regimens have more cumulative toxicity, financial impact, or patient convenience factors?
Community PollStarted

What factors have led you to reduce or d/c myeloma therapy for a patient with ongoing response?

30 physicians have voted

Join Mednetto vote and see how they answered.

3 Answers
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Massachusetts General Hospital
Answered on

After initial therapy (which may or may not include an autologous stem cell transplant), patients are generally on continuous/maintenance therapy with e.g. lenalidomide as the most common regimen. Most patients do well on this as maintenance. However, loose stools are probably the most common compla...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · University of Washington, Fred Hutchinson Cancer Research Center
Answered on

Completely agree with Dr. @Dr. First Last on all fronts. Assuming this question specifically pertains to lenalidomide maintenance, I'll also add:

1) If you're unsure whether your patient's symptoms are lenalidomide-related or not during maintenance, the difference between continuous lenalidomide (e....

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Mayo Clinic
Answered on

Alterations in therapy will be dictated by disease response as well as toxicity related to the therapy period. If the patient is not having a good disease response or if there is evidence of disease progression, one should consider changing the regimen completely with the introduction of new drugs i...

Join for free or sign in to see the full answer